These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19538242)

  • 1. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Diabet Med; 2009 Jun; 26(6):649-54. PubMed ID: 19538242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
    Lindsay JR; Duffy NA; McKillop AM; Ardill J; O'Harte FP; Flatt PR; Bell PM
    Diabet Med; 2005 May; 22(5):654-7. PubMed ID: 15842525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
    Thondam SK; Cross A; Cuthbertson DJ; Wilding JP; Daousi C
    Diabet Med; 2012 Aug; 29(8):e205-10. PubMed ID: 22486277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.
    Nagi DK; Ali VM; Yudkin JS
    Diabet Med; 1996 Aug; 13(8):753-7. PubMed ID: 8862952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
    Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
    Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
    Pala L; Mannucci E; Dicembrini I; Rotella CM
    Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
    Dai H; Gustavson SM; Preston GM; Eskra JD; Calle R; Hirshberg B
    Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A; Borot S; Raccah D
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
    Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
    Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*.
    Terra SG; Somayaji V; Schwartz S; Lewin AJ; Teeter JG; Dai H; Nguyen TT; Calle RA
    Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):401-7. PubMed ID: 21472661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.